Narrative review / 2014
Current clinical evidence for a therapeutic effect of high-dose intravenous vitamin C in cancer treatment is ambiguous.
This review evaluated the history and evidence surrounding high-dose intravenous (IV) vitamin C as an anticancer agent. Early reports claimed survival benefits, but subsequent oral randomized controlled trials showed no significant benefit, though pharmacokinetics differ substantially between oral and IV routes. In vitro data show vitamin C may act as a pro-oxidant at high concentrations, but clinical evidence remains ambiguous and largely limited to case series with poor correlation between plasma concentrations and response. Consequently, high-dose IV vitamin C cannot currently be recommended outside of a clinical trial.
- Study type
- Narrative review
- Who was studied
- Patients with cancer
- What was measured
- Anticancer therapeutic efficacy and survival benefit
THE PAPER
Review of high-dose intravenous vitamin C as an anticancer agent.
Wilson MK, Baguley BC, Wall C, Jameson MB, Findlay MP. Asia Pac J Clin Oncol, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.